



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/803,195	03/18/2004	Richard J. Feldmann	3399-Z	6156

7590 11/06/2007  
Law Office of Jim Zegeer  
Suite 108  
801 North Pitt Street  
Alexandria, VA 22314

EXAMINER
----------

BRUSCA, JOHN S

ART UNIT	PAPER NUMBER
----------	--------------

1631

MAIL DATE	DELIVERY MODE
-----------	---------------

11/06/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/803,195	FELDMANN, RICHARD J.	
	<b>Examiner</b>	<b>Art Unit</b>	
	John S. Brusca	1631	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 28 August 2007.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-16 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 28 August 2007 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☒ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                        | 4) <input type="checkbox"/> Interview Summary (PTO-413)                       |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)   |
| Paper No(s)/Mail Date _____   | 6) <input checked="" type="checkbox"/> Other: <u>See Continuation Sheet</u> . |

Continuation of Attachment(s) 6). Other: CRF Problem Report, CD Submission Review Results.

## **DETAILED ACTION**

### ***Priority***

1. The objection to the priority claim in the Office action mailed 28 February 2007 is withdrawn in view of the amendment to the specification filed 28 August 2007.

### ***Specification***

2. The amendment to the specification filed 28 August 2007 has been entered. The objection to the specification regarding lack of sequence identification numbers has been overcome.
3. The amendment filed 28 August 2007 is objected to under 37 CFR 1.52(e)(4) because it does not contain a statement in the transmittal letter that the two compact discs are identical. Correction is required.
4. The amendment filed 28 August 2007 contains data on compact disc(s). Compact disc labeled Copy 1 is not identified in the transmittal letter and/or the transmittal letter does not list for each compact disc, the machine format, the operating system compatibility, a list of files contained on the compact disc including their names, sizes in bytes, and dates of creation, plus any other special information that is necessary to identify, maintain, and interpret the information on the compact disc as required by 37 CFR 1.52(e)(3). A statement listing the required information is required.
5. The amendment filed 28 August 2007 contains data on compact disc(s). Compact disc labeled Copy 1 is not identified in the paper portion of the specification with a listing of all of the files contained on the disc. Applicant is required to amend the specification to identify each disc and the files contained on each disc including the file name, file size, and file creation date. See 37 CFR 1.52(e).

Art Unit: 1631

6. The amendment filed 28 August 2007 amends or adds a compact disc(s). See 37 CFR 1.77(b)(4) and 1.52(e)(5). Applicant is required to update or insert an incorporation-by-reference of the material on the compact disc(s) in the specification.

7. The amendment filed 28 August 2007 contains a data file on CD-ROM/CD-R that is not in an ASCII file format. File 3399-Z-PCT.as.amen is not in an ASCII format. Applicant is required to resubmit file(s) in ASCII format as required by 37 CFR 1.52(e)(3). No new matter may be introduced in presenting the file(s) in ASCII format. See the attached CRF Problem Report and CD Submission Review Results.

### *Drawings*

8. The replacement drawings filed 28 August 2007 have been accepted.

### *Claim Rejections - 35 USC § 112*

9. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-16 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention.

In *In re Wands* (8 USPQ2d 1400 (CAFC 1988)) the CAFC considered the issue of enablement in molecular biology. The CAFC summarized eight factors to be considered in a determination of "undue experimentation." These factors include: (a) the quantity of

Art Unit: 1631

experimentation necessary; (b) the amount of direction or guidance presented; (c) the presence or absence of working examples; (d) the nature of the invention; (e) the state of the prior art; (f) the relative skill of those in the art; (g) the predictability of the art; and (h) the breadth of the claims.

In considering the factors for the instant claims:

a) Quantity of experimentation: The only utility asserted by the specification is to use connectron symmetries to predict control of gene expression (see for example page 8 of the specification and the preamble of claims 1-8). In order to practice the claimed invention one of skill in the art must identify and use a connectron to predict regulation of gene expression. For the reasons discussed below, there would be an unpredictable amount of experimentation required to practice the claimed invention.

b) The amount of direction or guidance presented: The claimed invention is a method of identification of sequences that have a connectron relationship and act to modulate gene expression. On pages 9-13 the specification defines connectrons as a tetradic structure between two sequences in an RNA transcript of a genomic sequence and two sequences in double stranded genomic DNA. The specification speculates without evidence that triple-stranded (triplex) structures will form between RNA and double stranded DNA in chromatin where connectron symmetries are identified. The specification does not provide guidance that there are any limitations on formation of triplex structures, and only implies that regions of RNA with identical sequence to one strand of a double stranded DNA sequence will form triplex structures. The specification does not address why all RNA transcripts of genes would not form a continuous triplex structure with the gene from which it is transcribed. The specification provides guidance to identify connectron symmetries in genomic sequences on pages 16-17. The

Art Unit: 1631

specification does not provide detailed guidance to use identified connectron symmetries because the specification does not show whether or not connectrons form within cells or have an effect on gene expression. The specification does not provide specific guidance for monitoring or effecting changes in connectron behavior that correlate with gene expression.

c) The presence or absence of working examples: The specification provides working examples of identification of connectron symmetries by computer-mediated searching of genomic sequences. However, the specification does not provide evidence that connectron symmetries in genomic sequences result in formation of triplex RNA-DNA structures or that if connectron triplex structures do exist that connectrons control gene expression. The specification does not provide working examples of using identified connectron symmetries to predict effects on gene expression. The specification does not provide working examples of monitoring or effecting changes in connectron behavior that correlate with gene expression.

d) The nature of the invention: The nature of the invention, gene expression control, is complex.

e) The state of the prior art: One of skill in the art, after reading the specification, would not know that connectron symmetries identified by computer-mediated searches of genomic sequences would allow for prediction of gene expression of genes that have connectron symmetries. The specification does not provide experimental evidence that connectron symmetries cause modulation of gene expression. Neither the prior art nor post-filing art shows connectrons. Mattick reviews effects of RNA molecules on gene regulation. Mattick does not show connectrons as defined in the instant specification. Chan et al. reviews triplex DNA formation. Chan et al. shows in figures 1A-C that short stretches of oligonucleotides may form

Art Unit: 1631

parallel or antiparallel triplex structures. Chan et al. shows in figures 1B that parallel triplex forming oligonucleotides form bonds between C and T residues of the oligonucleotide and G and A residues of the double stranded DNA molecule. Figure 1C shows that antiparallel triplex forming oligonucleotides form bonds between A, G, and T residues of the oligonucleotide and A, G, and A residues of the double stranded DNA. Chan et al. characterize the limited range of base pairing possibilities in triplex structures as pyrimidine binding motifs or purine binding motifs. Chan et al. describe on pages 268-273 the unpredictability and difficulty of forming desired triplex structures that are limited to the purine motif or the pyrimidine motif. Chan et al. does not show a mechanism that allows for triplex structures to form with any and all regions of identity between an RNA transcript and a region of double stranded DNA that has an identical sequence in one of the two strands of DNA, as required for connectron formation as defined in the instant specification.

f) The relative skill of those in the art: The skill of those in the art of gene expression is high.

g) The predictability of the art: The predictability of the relationship of connectron symmetries and gene expression is unknown in the prior art and is not described in the instant specification.

h) The breadth of the claims: The claims are broad in that they are drawn to identification and design of connectron symmetries whose relationship to gene expression is not established.

The skilled practitioner would first turn to the instant specification for guidance in using the claimed invention. However, the specification lacks any evidence that connectrons form in cells or that connectron symmetries are related to gene expression. As such, the skilled



Art Unit: 1631

practitioner would turn to the prior art for such guidance, however the prior art does not discuss connectron symmetries. Chan et al. shows that triplex formation occurs only with oligonucleotides with a purine rich or pyrimidine rich motif, rather than with any identical sequence as suggested in the specification. Finally, said practitioner would turn to trial and error experimentation to determine a relationship between connectron symmetries and gene expression. Such amounts to undue experimentation.

***Response to Arguments***

10. Applicant's arguments filed 28 August 2007 have been fully considered but they are not persuasive.

The applicants state that the issues discussed in the rejection for lack of enablement under 35 U.S.C. 112, first paragraph are unrelated to the claimed subject matter, however enablement requires that one of skill in the art is enabled to use the claimed subject matter, and the rejection is maintained because the specification at the time of filing does not enable the use of the claimed subject matter. The applicants refer to the Vacatur mailed 28 September 2006 in Application No. 09/866925 in which the Board states that one of skill in the art would be enabled to generate data of connectron symmetries from a genome sequence. However, the applicants have not provided any evidence in the specification or their arguments that the triplex structure of connectrons form or can be used to predict or control gene expression. The applicants argue that the claim limitations do not require that the results of the claimed methods be used to predict or control gene expression, but enablement of the claimed subject matter does require that there is an enabled patentable utility for the claimed subject matter. For this reason the rejection is maintained because a use for the claimed subject matter is not enabled.

*Conclusion*

11. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to John S. Brusca whose telephone number is 571 272-0714. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marjorie A. Moran can be reached on 571-272-0720. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1631

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/John S. Brusca/  
Primary Examiner  
Art Unit 1631

jsb

**NOTICE TO COMPLY WITH  
SEQUENCE RULES**

**Application No.**

10/803,195

**Examiner**

John S. Brusca

**Applicant(s)**

FELDMANN, RICHARD J.

**Art Unit**

1631

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reasons:

- ☐ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing in computer readable form has been submitted. However the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked up "Raw Sequence Listing".
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. A Substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☒ 7. Other: The CD containing the computer readable form was not entered, see attached CRF Problem Report and CD Submission Review Results. The CD containing the Sequence Listing is the wrong media type, see CD Submission Review Results. A substitute CD for the CRF and a substitute CD or paper copy of the Sequence Listing is required, as well as a statement of identity.

**Applicant must provide:**

- ☐ An initial or ☒ A substitute computer readable form copy of the Sequence Listing.
- ☐ An initial or ☒ A Substitute paper copy of the Sequence Listing as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same, and, where applicable, include no new matter, as required by 37 CFR 1.821(e), (f), or (g) or 1.825(b) or (d).

**FOR QUESTIONS PLEASE CONTACT:**

Rules Interpretation (703) 308-4216  
CRF Submission Help (703) 308 4212  
PatentIn software help (703) 308 6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

## CD Submission Review Results

Application Number	10 803/95	Receipt Date	8 28 07
--------------------	-----------	--------------	---------

<input checked="" type="checkbox"/> New Application		Response to Notice	Date of Response	
---	--	--------------------	------------------	--

☐ Jumbo – Large tables are included on the CD Page Count \_\_\_\_\_

☐ There are no problems with the CDs in the submission.

Items checked below are to be selected in the PALM Pre-Exam CD problem list.

## Omitted Items

- ☐ Files on compact disc are unreadable:
- ☐ Disc(s) of either set not readable:
- ☐ Disc(s) do not contain file names listed:
- ☐ Amended CD missing unamended files:
- ☐ Missing compact discs:

## Missing Parts

- ☐ Disc(s) do not contain file names listed:
- ☐ Discs contains files that are non-ASCII files:
- ☐ Only one copy of the CD, no duplicate:
- ☒ Wrong media type, e.g., CD-RW:
- ☐ The transmittal letter and specification do not list information:
- ☐ Both disc(s) contain unreadable files:
- ☐ One disc(s) contain unreadable files:
- ☐ Compact disc(s) contain viruses, but are still readable:
- ☐ EFS/Paper Submission:
- ☐ Table does not maintain data in proper alignment:
- ☐ Not proper subject matter for CD's:

Informality – If no problem, do not send notice, leave letter for Examiner

- ☐ No statement in transmittal letter that CD's are the same:
- ☐ No incorporation by reference statement for the CD's:
- ☐ CD's not labeled "Copy 1" and "Copy 2":
- ☐ Deficient CD packaging:
- ☐ Deficient Labeling on CD's:
- ☐ The transmittal letter does not list information:
- ☐ The specification does not list information:
- ☐ Table less than 51 pages submitted on CD:

## File Directory Attachment

- ☒ Copy of file directory listing is attached and should be mailed to applicant
- ☐ Copy of file directory listing is not attached
- ☐ Copy of file directory listing is not attached because it is over one page long

```

<110>      Feldmann, Richard J.
<120>      Symmetry relationships between pairs of Connectrons
<130>      Jim Zegeer Law Offices - 703-684-8333
<140>      US and/or PCT number
<141>      28 August 2007

<160>      288

<170>      Proprietary

<210>      1

<211>      182
<212>      DNA
<213>      Escherichia coli K-12 MG1655 complete genome

<220>
<222>      (4505026)...(4505207)
<223>      Chromosome = 1 Contig = 1 Strand = pos CtronObjNum = 7435

<400>      1
ctgtagattc aatctgtcaa tgcaacaccc ctttcaatta tctctttcgg tgttttgaac      60
ttcagtgctt ttctcgggtct gttgttttagc tgagcagcaa ccagatctag ttcattgttga      120
gtatattggg caagacatgt ctttttagga aagtactgcc gaattagccc atttgtgttc      180
tc                                              182

<210>      2

<211>      182
<212>      DNA
<213>      Escherichia coli K-12 MG1655 complete genome

<220>
<222>      (279155)...(279336)
<223>      Chromosome = 1 Contig = 1 Strand = neg CtronObjNum = 508

<400>      2
ctgtagattc aatctgtcaa tgcaacaccc ctttcaatta tctctttcgg tgttttgaac      60
ttcagtgctt ttctcgggtct gttgttttagc tgagcagcaa ccagatctag ttcattgttga      120
gtatattggg caagacatgt ctttttagga aagtactgcc gaattagccc atttgtgttc      180
tc                                              182

<210>      3

<211>      171
<212>      DNA
<213>      Escherichia coli K-12 MG1655 complete genome

<220>
<222>      (4505031)...(4505201)
<223>      Chromosome = 1 Contig = 1 Strand = pos CtronObjNum = 7435

<400>      3

```

Volume in drive D:\ is Aug 24 2007  
Directory of D:\

3399-Z-PCT.as.amen

101 KB

8/15/07

1 file(s)

Total filesize 101 KB

0 kilobytes free



## **SCORE**

### **CRF Problem Report**

**SCORE experienced a problem when processing the following computer readable form (CRF):**

Application Serial Number: 10/003,195  
Filing Date: 8/28/07  
Date Processed by SCORE: 9-4-07

**Contact: Electronic Business Center: Telephone: 866-217-9197**

#### **Nature of CRF Problem:**

- ☐ (circle one) Damaged or Unreadable
- ☐ Blank (no files on CRF)
- ☐ Empty file (filename present, but no bytes in file)
- ☐ Wrong file saved to CRF (invention title, docket number, or applicant(s) do not match those in official application)
- ☒ Not saved in ASCII text
- ☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing.
- ☐ Did not contain a Sequence Listing.
- ☐ Other:

**PLEASE USE THE CHECKER VERSION 4.4.0 PROGRAM TO REDUCE ERRORS.  
SEE BELOW FOR ADDRESS:**

**<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>**

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):  
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/20/06